NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.


This presentation begins with an overview of disease state information, including a discussion of the definition of severe asthma and the proportion of the total asthma population who have severe asthma with an eosinophilic phenotype. An overview of the mechanism of action of NUCALA is also included.

825656R0 September 2017